Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms

Br J Haematol. 2016 Feb;172(4):628-30. doi: 10.1111/bjh.13516. Epub 2015 Jun 10.

Raynier Devillier^{1

2}, Emmanuel Raffoux³, Jérôme Rey¹, Etienne Lengline³, Anne-Marie Ronchetti³, Marie Sebert⁴, Nicolas Boissel^{5

6}, Marie Robin⁷, Norbert Vey^{1

2}, Jean-Jacques Kiladjian^{3

6

8}, Herve Dombret^{3

6}, Thomas Cluzeau^{9

10

11}

¹ Haematology Department, Institut Paoli Calmettes, Marseille, France.
² Aix-Marseille University, Marseille, France.
³ Adult Haematology Department, Saint Louis Hospital, Paris, France.
⁴ Senior Haematology Department, Saint Louis Hospital, Paris, France.
⁵ Adolescents and Young Adults Haematology Department, Saint Louis Hospital, Paris, France.
⁶ EA3518, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.
⁷ Allo Stem Cell Transplantation Department, Saint Louis Hospital, Paris, France.
⁸ Centre d'Investigation Clinique (CIC), Saint Louis Hospital, Paris, France.
⁹ Adult Haematology Department, Saint Louis Hospital, Paris, France. [email protected].
¹⁰ EA3518, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France. [email protected].
¹¹ INSERM U1065, Centre mediterraneen de Medecine Moleculaire, Nice, France. [email protected].

No abstract available

Keywords: acute myeloid leukaemia; blast phase; intensive chemotherapy; myeloproliferative neoplasm; ruxolitinib.

Publication types